Ocular Therapeutix, Inc. (OCUL) Financial Analysis & Valuation | Quarter Chart
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent... more
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $1.64B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Pravin U. Dugel |
| IPO Date | 2014-07-25 | CAGR | 93.08% |
| Employees | 325 | Website | www.ocutx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.01% | Total Yield | -0.01% |
OCUL chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $1.46B | P/E | -5.29 | Forward P/E | -4.97 | PEG | — |
| P/S | 10333.88 | P/B | 1061.09 | P/CF | -2312.79 | P/FCF | -2110.31 |
| Sales | $52.05M | Sales 1Y | -8.14% | Sales 3Y | -4.66% | Sales 5Y | 61.23% |
| EPS | $-1.42 | EPS 1Y | 10.94% | EPS 3Y | 18.33% | EPS 5Y | -24.06% |
| Sales QoQ | 24.94% | EPS QoQ | -12.5% | Sales QoQ Avg | 1.38% | EPS QoQ Avg | -0.2% |
| Gross Margin | 87.11% | Operating Margin | -603.04% | Profit Margin | -579.1% | ROCE | -50.46% |
| ROA | -45% | ROE | -60% | Altman Z Score | 3.26 | Piotroski Score | 2 |
| Current Ratio | 13.11 | Quick Ratio | 13.03 | Cash Ratio | 12.17 | Op. CF Ratio | -1.37 |
| Debt/Equity | 0.15 | Debt/Assets | 0.12 | Lt Debt/Equity | 0.15 | Lt Debt/Cap. | 0.13 |
| Intrst Cov. | -1184.56 | Inventory Turnover | 1.75 | Asset Turnover | 0.08 | Receivables Turnover | 1.72 |
| Enterprise Value | $1.46B | P/E Ratio | -5.29 |
| Forward P/E | -4.97 | PEG Ratio | — |
| P/S Ratio | 10333.88 | P/B Ratio | 1061.09 |
| P/CF Ratio | -2312.79 | P/FCF Ratio | -2110.31 |
| EPS | $-1.42 | EPS Growth 1Y | 10.94% |
| EPS Growth 3Y | 18.33% | EPS Growth 5Y | -24.06% |
| Revenue Growth 1Y | -8.14% | Gross Margin | 87.11% |
| Operating Margin | -603.04% | Profit Margin | -579.1% |
| ROE | -60% | ROA | -45% |
| ROCE | -50.46% | Current Ratio | 13.11 |
| Quick Ratio | 13.03 | Cash Ratio | 12.17 |
| Debt/Equity | 0.15 | Interest Coverage | -1184.56 |
| Altman Z Score | 3.26 | Piotroski Score | 2 |
Ocular Therapeutix, Inc. (OCUL) valuation & financials
Ocular Therapeutix, Inc. (OCUL) has a market capitalization of $1.64B and trades at a price-to-earnings ratio of -5.3. It operates in the Healthcare sector (Biotechnology).
Ocular Therapeutix, Inc.'s revenue grew -8.1% over the last year.
Ocular Therapeutix, Inc.'s next earnings report is scheduled for November 3, 2026 (provider scheduled date); analysts estimate EPS of $-0.36. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)